Antares Pharma Inc. (NASDAQ:ATRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “

Separately, Piper Jaffray Cos. reiterated an “overweight” rating and set a $2.00 price objective (down previously from $3.00) on shares of Antares Pharma in a research report on Saturday, August 13th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Antares Pharma (NASDAQ:ATRS) traded down 1.11% during trading on Tuesday, hitting $1.78. 579,111 shares of the company traded hands. Antares Pharma has a 52 week low of $0.67 and a 52 week high of $1.85. The company’s market capitalization is $276.00 million. The company has a 50 day moving average price of $1.49 and a 200 day moving average price of $1.12.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Antares Pharma had a negative net margin of 54.98% and a negative return on equity of 41.06%. The business earned $12.20 million during the quarter, compared to analyst estimates of $11 million. During the same quarter last year, the business earned ($0.01) earnings per share. On average, analysts expect that Antares Pharma will post ($0.15) earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in ATRS. Jane Street Group LLC purchased a new stake in Antares Pharma during the second quarter valued at about $133,000. Paloma Partners Management Co purchased a new stake in Antares Pharma during the second quarter valued at about $607,000. Janus Capital Management LLC purchased a new stake in Antares Pharma during the second quarter valued at about $102,000. Laurion Capital Management LP purchased a new stake in Antares Pharma during the second quarter valued at about $467,000. Finally, JW Asset Management LLC raised its stake in Antares Pharma by 234.7% in the second quarter. JW Asset Management LLC now owns 475,897 shares of the specialty pharmaceutical company’s stock valued at $500,000 after buying an additional 333,699 shares during the period. Hedge funds and other institutional investors own 36.34% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

5 Day Chart for NASDAQ:ATRS

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with's FREE daily email newsletter.